- Coordinator
- Universitatsklinikum Erlangen, Germany
- Runs
- 1 June 2023 to 31 May 2027
- Status
- Running
- EU funding
- €8.0m
- Total cost
- €8.0m
- Partners
- 17 organisations in 8 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101080580
What the project is doing
In the project's own words, from its summary on CORDIS.
Cardio-facio-cutaneous syndrome, Costello syndrome and SYNGAP1-related encephalopathy are rare neurodevelopmental RASopathies manifesting with severe intellectual disability, seizures and autism spectrum disorder. These symptoms are underdiagnosed and lack approved therapeutic options. EURAS aims to develop new effective therapies and operative disease management for RASopathies. With strong support of patient organizations from 13 countries, a new patient report-based registry for stratification of patient cohorts and evaluation of treatments will be implemented.
To clarify the pathophysiology of RASopathies and to identify cellular/molecular “disease signatures” as biomarkers for drug screening and for therapy validation, EURAS will generate new and employ existing disease models. Phenotypical screenings of drug libraries assisted by automated high-resolution, high-content pipelines will be conducted on differentiated, electrically active patient iPSC-derived neurons. Preclinical proof-of-concept trials with repurposed drugs, antisense oligonucleotides and motor-cognitive training will be performed to achieve reversal of seizures and autistic behavioural traits in animal models.
To provide patients with less invasive treatments, new technologies for efficient drug delivery of treatments to the brain will be developed and validated. Finally, EURAS establishes Europe-wide patient association to improve awareness and exchange between affected families and to foster their access to knowledge and therapies. With all these measures, EURAS delivers new effective therapies and set the frame for early and accurate diagnosis of neurological symptoms in RASopathies, which are not available at present.
Moreover, some results of EURAS will be widely transferable, fostering development of therapies even for unrelated diseases. Thus, EURAS will sustainably improve the lives of affected people and strengthen expertise of health systems in Europe and worldwide.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitatsklinikum Erlangen | Erlangen | Germany | Coordinator |
| Ait Austrian Institute of Technology GmbH | Wien | Austria | Participant |
| Paracelsus Medizinische Privatuniversitat Salzburg - Privatstiftung | Salzburg | Austria | Participant |
| Eurice European Research and Project Office GmbH | St Ingbert | Germany | Participant |
| Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften eV | Munchen | Germany | Participant |
| Neuway Pharma GmbH | Bonn | Germany | Participant |
| Otto-Von-Guericke-Universitaet Magdeburg | Magdeburg | Germany | Participant |
| Ruprecht-Karls-Universitaet Heidelberg | Heidelberg | Germany | Participant |
| Syngap Elternhilfe E. V | Krefeld | Germany | Participant |
| Universitaet Ulm | Ulm | Germany | Participant |
| Zentralinstitut Fuer Seelische Gesundheit | Mannheim | Germany | Participant |
| Universidad De Malaga | Malaga | Spain | Participant |
| Turun Yliopisto | Turku | Finland | Participant |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Participant |
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Participant |
| Ist-Id Associacao Do Instituto Superior Tecnico Para a Investigacao E O Desenvolvimento | Lisboa | Portugal | Participant |
| The University of Edinburgh | Edinburgh | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI